NASDAQ · RNXT
Healthcare · Biotechnology
$1.32
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 1:15 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RNXT closed at $1.32 after 20 trading sessions, up 36.77% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.30 | $1.325 | $1.25 | $1.32 | 233.27K |
| Aug 20, 2026 | $1.29 | $1.35 | $1.23 | $1.32 | 381.18K |
| Aug 19, 2026 | $1.17 | $1.3372 | $1.15 | $1.315 | 582.34K |
| Aug 18, 2026 | $1.21 | $1.2686 | $1.12 | $1.17 | 498.97K |
| Aug 17, 2026 | $1.415 | $1.505 | $1.1799 | $1.20 | 1.22M |
| Aug 14, 2026 | $1.27 | $1.45 | $1.26 | $1.40 | 1.01M |
| Aug 13, 2026 | $1.12 | $1.30 | $1.12 | $1.26 | 993.81K |
| Aug 12, 2026 | $1.14 | $1.16 | $1.10 | $1.12 | 477.07K |
| Aug 11, 2026 | $1.16 | $1.20 | $1.12 | $1.15 | 361.52K |
| Aug 10, 2026 | $1.14 | $1.16 | $1.09 | $1.16 | 317.7K |
| Aug 7, 2026 | $1.17 | $1.20 | $1.10 | $1.12 | 317.83K |
| Aug 6, 2026 | $1.07 | $1.18 | $1.07 | $1.15 | 693.6K |
| Aug 5, 2026 | $1.06 | $1.0999 | $1.04 | $1.06 | 316.72K |
| Aug 4, 2026 | $0.9811 | $1.06 | $0.98 | $1.04 | 401.84K |
| Aug 3, 2026 | $0.9653 | $1.0999 | $0.95 | $1.06 | 703.84K |
| Jul 31, 2026 | $0.95 | $0.97 | $0.9234 | $0.9583 | 244.99K |
| Jul 30, 2026 | $0.91 | $0.9499 | $0.91 | $0.9412 | 113.57K |
| Jul 29, 2026 | $0.91 | $0.9296 | $0.8866 | $0.8981 | 127.62K |
| Jul 28, 2026 | $0.9325 | $0.9699 | $0.88 | $0.9073 | 219.74K |
| Jul 27, 2026 | $0.90 | $0.98 | $0.871 | $0.9651 | 868.8K |
The latest Smart Investors Daily articles mentioning RNXT.
RNXT research
Company profile and research snapshot.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 1, 2026 | Ascendiant Capital | Buy | — |
| Apr 9, 2026 | Ascendiant Capital | Buy | — |
| Apr 8, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 17, 2026 | Ascendiant Capital | Buy | — |
| Aug 25, 2025 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
Benzinga · Aug 12, 2026
RenovoRx (NASDAQ:RNXT) raises FY2026 sales outlook from $3.000 million-$4.000 million to $3.750 million-$4.250 million vs $3.203 million estimate.
Benzinga · Aug 12, 2026
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per share from the same
Benzinga · Aug 11, 2026
RenovoRx finishes Phase 3 TIGeR-PaC trial enrollment for locally advanced pancreatic cancer, expecting topline data in H2 2027.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RNXT.
